Crux and Pfizer Win PDA Drug Delivery Innovation Award
We’re pleased to announce that Crux, in collaboration with Pfizer won the PDA Drug Delivery Innovation Award at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024.
Our joint submission, “3D Imaging and Analysis of Large Volume (20mL) Viscous (25cP) Injections with Fast Delivery Rates (10mL/min) in a Porcine Model: Risks and Opportunities”, was recognised for its significant contribution to advancing the field of bio/pharmaceutical drug delivery.
Led by Joel Gresham, Lead Applied Sciences Engineer at Crux and Simon Dell, Senior Principal Scientist at Pfizer, the project addresses a critical challenge in the pharmaceutical industry.
Why This Research Matters
Biologic drugs represent the future of pharmaceutical treatments, offering new possibilities for patients with complex conditions. However, these drugs often require high doses to be effective, presenting challenges in drug delivery.
Our research explores the limits of subcutaneous injections, focusing on:
- Large Volume Delivery: Investigating how to safely and effectively deliver high doses of medication.
- High Viscosity: Addressing the challenges of injecting thick, concentrated formulations.
- Rapid Delivery: Exploring ways to administer these large volumes quickly for patient convenience.
Key Aspects of Our Study
Our innovative approach utilised 3D imaging and analysis in a porcine model to examine:
- Device-skin interactions in large-volume delivery
- Strategies for leakage prevention and ensuring consistent dosing
- The impact of patient variability on PK and bioavailability
- Assessment of pain and tolerability factors
Our study provides valuable insights into the risks and opportunities associated with advanced drug delivery methods, paving the way for more effective and patient-friendly treatments.
Joel Gresham of Crux and Simon Dell of Pfizer being awarded the PDA Drug Delivery Innovation Award at the PDA Universe of Pre-Filled Syringes and Injection Devices Conference 2024.
Moving Forward
The award recognises our team’s hard work and innovation and reinforces our commitment to improving patient care and treatment efficacy. As we continue to push the boundaries of drug delivery technology, we remain focused on developing solutions that enhance the patient experience and improve treatment outcomes.
We’re incredibly proud of Joel, Simon, and the entire team at Crux and Pfizer who contributed to this innovative work. The achievement highlights the power of collaboration between forward-thinking consultancies and pharmaceutical leaders in driving advancements in healthcare.
Keep an eye out for more updates as we continue our work to transform drug delivery systems and improve patient care.
Read the full press release from PDA here, or if you would like to chat with us about our work, get in touch.